Chat with Filing

Ask questions about this document
Please log in or register to use the chat feature. Please register first.
RNS - Evotec creates long-term growth opportunities by initiating 'Campus Levi-Montalcini' in Verona

Company: Evotec SE Date: 2021-07-01 Language: English Register to download
Loading document preview...
Document Preview Not Available

The file type (.html) cannot be displayed directly here.
Open Original File
Error loading document preview. Please try the 'Open Original File' link.
You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:
Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon
 News Details

Corporate | 1 July 2021 07:30

#   

Evotec creates long-term growth opportunities by initiating ‘Campus Levi-Montalcini’ in Verona

DGAP-News: Evotec SE / Key word(s): Miscellaneous  

01.07.2021 / 07:30  

The issuer is solely responsible for the content of this announcement.  

-   *EVOTEC ACQUIRES THE VERONA SITE FROM GSK AND SECURES CAPACITY FOR LONG-TERM GROWTH*
-   *EMPLOYEES VOTE FOR SITE TO BE NAMED “CAMPUS LEVI-MONTALCINI” IN HONOUR OF ITALIAN NOBEL LAUREATE RITA LEVI-MONTALCINI*

  

**Hamburg, Germany, 01 July 2021:**  

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA (“GSK”). During a site meeting, the employees also decided on a new name for their campus. In commemoration of Italian Nobel laureate Rita Levi-Montalcini, the Verona site will be named “Campus Levi-Montalcini” going forward.  

  

Campus Levi-Montalcini is one of Evotec’s fully integrated powerhouses that offers expertise, capacity, capabilities and know-how in integrated R&D. The site comprises all technologies and services needed to develop a drug discovery project from the idea, through pre-clinical and clinical development, all the way to the market – including INDiGO, the Company’s integrated and interdisciplinary service for accelerated drug development as well as broad and deep expertise in API manufacturing, pre-formulation and cGMP manufacturing of the drug product.  

  

Evotec has been operating at its Verona site since acquiring Aptuit in 2017 and currently employs approximately 750 employees on Campus Levi-Montalcini. Both the existing buildings as well as the plot hold further potential to enter the next growth phase in Verona and continue to build capacity as needed to support the Company’s global strategic framework Action Plan 2025: “The data-driven R&D Autobahn to Cures”.  

  

**Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented:** “Evotec is committed to its vision of efficiently delivering new and highly effective therapeutics to patients who urgently need them. In order to truly deliver on this mission, our sustainable growth strategy builds on complementary clusters of excellence. Acquiring the site will give us plenty of opportunities to further grow our business in Verona and we are proud to call the site Campus Levi-Montalcini.”  

  

**Dr Ciriaco Maraschiello, EVP, Global Head of Drug Development and Verona Site Head, added:** “The acquisition of the Verona R&D campus from GSK, one of the major R&D centres in the country, means continuity and further development of R&D excellence in Italy. Becoming the owner of the Verona R&D facility strengthens Evotec’s fully integrated R&D solutions for our partners. This is also an opportunity to create the right environment on site to continue to be the best at what we do every day; contributing to the discovery and development of better medicines and ultimately improving the quality of life for patients.”  

  

No financial details of the transaction were disclosed.  

  

  

**About Rita Levi-Montalcini**  

Rita Levi-Montalcini was born in Turin in 1909. At age twenty, she asked her father permission to engage in a professional career, graduated from high school, and enrolled in medical school. Like her contemporaries Salvador Luria (Nobel laureate 1969) and Renato Dulbecco (Nobel laureate 1975), Levi-Montalcini was a student of the famous Italian histologist, Giuseppe Levi.  

  

After graduating medical school *summa cum laude* in 1936, Levi-Montalcini enrolled in a three-year specialisation course in neurology and psychiatry. Returning from a visit to a neurological institute in Brussels shortly before the German invasion of Belgium, Levi-Montalcini and her family, who were Jewish, faced the barring of academic and professional careers to non-Aryan citizens in Italy. During this time, Levi-Montalcini built up a small research facility in her own bedroom.  

  

After the war, Levi-Montalcini resumed her academic career at the University of Turin, but in 1947 she received an invitation from Viktor Hamburger to join him at Washington University in St. Louis. What was initially planned as a ten to twelve month stay turned into a life-changing decision. It was there that, in 1952, Levi-Montalcini did her most important work: isolating nerve growth factor (“NGF”) from certain cancerous tissues. Rita Levi-Montalcini stayed in St. Louis more than a decade, becoming an Associate Professor in 1956, and a full Professor in 1958. After establishing a second research unit in Rome in 1962, she divided her time between Rome and St. Louis, further building on the research with Stanley Cohen on the NGF antibodies. In 1986, both Rita Levi-Montalcini and Stanley Cohen were awarded the Nobel Prize in Physiology or Medicine for their foundational work in this field. [\[1\]](#footnote_1)  

  

  

*ABOUT EVOTEC SE  

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to* [www.evotec.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d9f30c4aeb65d3276d5bd878be7dc75c&application_id=1214104&site_id=news_data&application_name=news) *and follow us on Twitter* [@Evotec](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b578791509083b40bb44fb801a96a7b5&application_id=1214104&site_id=news_data&application_name=news) *and* [LinkedIn](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ec4860b9e471078d0d9c387b209cbfb1&application_id=1214104&site_id=news_data&application_name=news) *.  

  

FORWARD-LOOKING STATEMENTS*  

*Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*  

  

Media Contact Evotec SE:  

Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, [gabriele.hansen@evotec.com](mailto:gabriele.hansen@evotec.com)  

  

IR Contact Evotec SE:  

Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, [volker.braun@evotec.com](mailto:volker.braun@evotec.com)  

  

\[1\] Sources: https://www.nobelprize.org/prizes/medicine/1986/levi-montalcini/biographical/; Chao MV, Calissano P. Rita Levi-Montalcini: in memoriam. Neuron. 2013 Feb 6;77(3):385-7. doi: 10.1016/j.neuron.2013.01.019. PMID: 23527384.

  

- - -

01.07.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.  

The issuer is solely responsible for the content of this announcement.  

  

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.dgap.de  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Evotec SE |
|     | Manfred Eigen Campus / Essener Bogen 7 |
|     | 22419 Hamburg |
|     | Germany |
| Phone: | +49 (0)40 560 81-0 |
| Fax: | +49 (0)40 560 81-222 |
| E-mail: | info@evotec.com |
| Internet: | www.evotec.com |
| ISIN: | DE0005664809 |
| WKN: | 566480 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1214104 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | DGAP News Service |

![show this](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1214104&application_name=news&site_id=news_data)